Out of stock
Tirzepatida
30 mg / 3 ml
Summary
Dual GLP-1 and GIP receptor agonist. A 39-amino-acid peptide that activates both incretin pathways for a synergistic metabolic effect.
Benefits
- Glycemic control: supports glucose-dependent insulin secretion.
- Prolonged satiety: slows gastric emptying and helps reduce appetite.
- Metabolic support: suppresses glucagon in a glucose-dependent manner.
Suggested protocol
Reconstitution and dose 30 mg / 3 ml — weekly dose
Weeks 1-4: 2.5 units
Weeks 5-8: 5.0 units
Weeks 9-12: 7.5 units
Weeks 13-16: 10 units (for obesity)
Maintenance: 2.5 units
Vials by duration (reference)
8 weeks: 1 vial
12 weeks: 2 vials
16 weeks: 4 vials
Complementary-use product; it does not replace a medical diagnosis. Consult your therapist before use.